DJIA 15,307.17 -80.41 -0.52%
NASDAQ 3,463.30 -38.82 -1.11%
S&P 500 1,655.35 -13.81 -0.83%

Biogen Idec

NASDAQ: BIIB

+ Add to Portfolio

company name or ticker
Company Photos
(Click to zoom)
Working at Biogen Idec

Additional Patent for Acorda's Ampyra - Analyst Blog

Additional Patent for Acorda's Ampyra - Analyst Blog
5/22/2013 by Zacks

Cramer's 'Mad Money' Recap: Ignore the Fed

5/22/2013 by TheStreet

Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference

5/22/2013 by DailyFinance

Biogen Idec Stock Hits New 52-Week High (BIIB)

5/22/2013 by TheStreet

Positive Data on Novo Nordisk's N9-GP - Analyst Blog

Positive Data on Novo Nordisk's N9-GP - Analyst Blog
5/21/2013 by Zacks

Another Multiple Sclerosis Winner for Biogen

Biogen submits Plegridy for FDA approval.
5/21/2013 by DailyFinance

1 Big Pharma Phase 3 Failure

Pfizer's non-Hodgkin's lymphoma drug saw its phase 3 trial halted for lack of efficacy.
5/21/2013 by DailyFinance

When Savvy Dealmaking Borders on Reckless Spending

Is Elan deftly making deals or blowing its newfound cash hoard?
5/21/2013 by DailyFinance

Biogen Idec Submits BLA to FDA for Approval of PLEGRIDY for Multiple Sclerosis

5/21/2013 by Benzinga

Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple

5/21/2013 by DailyFinance
See More Articles...